Debt-to-equity of ImmunityBio, Inc. from 31 Mar 2016 to 31 Dec 2025
- Taxonomy & unit
- ratio: x
- Description
- Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's debt by its shareholder equity.
- Summary
-
ImmunityBio, Inc. quarterly Debt-to-equity in x history and change rate from 31 Mar 2016 to 31 Dec 2025.
- ImmunityBio, Inc. Debt-to-equity for the quarter ending 31 Dec 2025 was -1.79x, a 11% decline year-over-year.
Debt-to-equity, Quarterly (x)
Debt-to-equity, YoY Quarterly Change (%)
ImmunityBio, Inc. Quarterly Debt-to-equity (x)
| Period | Value | YoY Chg | Change % | Date |
|---|---|---|---|---|
| Q4 2025 | -1.79x | -0.18x | -11% | 31 Dec 2025 |
| Q3 2025 | -1.74x | -0.11x | -6.7% | 30 Sep 2025 |
| Q2 2025 | -1.6x | +0.14x | +8% | 30 Jun 2025 |
| Q1 2025 | -1.59x | +0.11x | +6.3% | 31 Mar 2025 |
| Q4 2024 | -1.61x | +0.12x | +7% | 31 Dec 2024 |
| Q3 2024 | -1.63x | +0.08x | +4.7% | 30 Sep 2024 |
| Q2 2024 | -1.74x | -0.08x | -4.7% | 30 Jun 2024 |
| Q1 2024 | -1.7x | +0.06x | +3.5% | 31 Mar 2024 |
| Q4 2023 | -1.73x | +0.15x | +8.1% | 31 Dec 2023 |
| Q3 2023 | -1.71x | +0.37x | +18% | 30 Sep 2023 |
| Q2 2023 | -1.67x | +0.51x | +24% | 30 Jun 2023 |
| Q1 2023 | -1.76x | +0.67x | +28% | 31 Mar 2023 |
| Q4 2022 | -1.88x | +0.6x | +24% | 31 Dec 2022 |
| Q3 2022 | -2.08x | +0.29x | +12% | 30 Sep 2022 |
| Q2 2022 | -2.18x | +1.54x | +41% | 30 Jun 2022 |
| Q1 2022 | -2.43x | -64.98x | -104% | 31 Mar 2022 |
| Q4 2021 | -2.48x | -3.88x | -276% | 31 Dec 2021 |
| Q3 2021 | -2.37x | -3.14x | -408% | 30 Sep 2021 |
| Q2 2021 | -3.72x | -4.49x | -581% | 30 Jun 2021 |
| Q1 2021 | 62.54x | +61.74x | +7679% | 31 Mar 2021 |
| Q4 2020 | 1.4x | +0.68x | +93% | 31 Dec 2020 |
| Q3 2020 | 0.77x | +0.54x | +230% | 30 Sep 2020 |
| Q2 2020 | 0.77x | +0.52x | +211% | 30 Jun 2020 |
| Q1 2020 | 0.8x | +0.56x | +227% | 31 Mar 2020 |
| Q4 2019 | 0.73x | +0.51x | +238% | 31 Dec 2019 |
| Q3 2019 | 0.23x | +0.06x | +36% | 30 Sep 2019 |
| Q2 2019 | 0.25x | +0.09x | +60% | 30 Jun 2019 |
| Q1 2019 | 0.25x | +0.08x | +49% | 31 Mar 2019 |
| Q4 2018 | 0.22x | +0.07x | +46% | 31 Dec 2018 |
| Q3 2018 | 0.17x | +0.04x | +32% | 30 Sep 2018 |
| Q2 2018 | 0.16x | +0.05x | +48% | 30 Jun 2018 |
| Q1 2018 | 0.16x | +0.09x | +130% | 31 Mar 2018 |
| Q4 2017 | 0.15x | +0.09x | +154% | 31 Dec 2017 |
| Q3 2017 | 0.13x | +0.08x | +186% | 30 Sep 2017 |
| Q2 2017 | 0.11x | +0.07x | +214% | 30 Jun 2017 |
| Q1 2017 | 0.07x | +0.04x | +129% | 31 Mar 2017 |
| Q4 2016 | 0.06x | 31 Dec 2016 | ||
| Q3 2016 | 0.05x | 30 Sep 2016 | ||
| Q2 2016 | 0.03x | 30 Jun 2016 | ||
| Q1 2016 | 0.03x | 31 Mar 2016 |
* An asterisk sign (*) next to the value indicates that the value is likely invalid.